Semaglutide news: the key developments shaping treatment in 2025 and 2026

What happened with the 7.2mg dose, and why does a higher dose matter?

For most of its life as a weight-management medicine in the UK, Wegovy's ceiling was 2.4mg once weekly. That changed in January 2026, when the MHRA approved a 7.2mg maintenance dose, initially supplied as three separate 2.4mg pens used in the same week. Then, on 14 April 2026, came the next step: a single pre-filled pen delivering 7.2mg in one injection, with an auto-dosing mechanism and a built-in covered needle that locks after use. The approval covers adults with a BMI of 30 or above. It does not extend to the cardiovascular indication or to people with a BMI below that threshold.

Why does a higher dose matter clinically? Trial data reported around 20.7% average weight loss over 72 weeks at 7.2mg, narrowing the gap with tirzepatide 15mg results seen in the SURMOUNT programme. That puts it meaningfully above the roughly 15% seen in the STEP 1 trial at 2.4mg. The titration schedule stays the same: treatment starts at 0.25mg and works upward in steps set by the prescriber, with 7.2mg as the new maximum. Specific dose availability is always confirmed at consultation, since supply can vary. For a broader look at how Wegovy works and who it's licensed for, our overview covers the full picture.

The approval was announced by the MHRA on 14 April 2026 and is the clearest signal yet that regulators and manufacturers see semaglutide as a long-term, evolving treatment rather than a single fixed product, something our Wegovy news pages have been tracking as each development lands.

What is the Wegovy tablet, and how is oral semaglutide different from the injection?

The most discussed piece of recent semaglutide news is probably the tablet. On 11 June 2026 the MHRA approved Wegovy tablets (oral semaglutide co-formulated with an absorption enhancer called SNAC) making the UK the first country in Europe to license an oral GLP-1 medicine for weight management. That is not a small footnote; it represents a genuine shift in who might practically consider this treatment.

The dosing schedule runs once daily, starting at 1.5mg and escalating through 4mg and 9mg to a 25mg maintenance dose, with at least a month spent at each level. The tablet is taken first thing in the morning on an empty stomach with a small amount of plain water, and the patient waits at least thirty minutes before eating, drinking anything else, or taking other oral medicines. No refrigeration is needed, which is genuinely useful for people who travel, work irregular hours, or simply find the idea of keeping medication in the fridge inconvenient.

Trial evidence from OASIS 4 (64 weeks, 307 adults with obesity or overweight plus at least one weight-related condition, without diabetes) showed an average weight loss of around 13.6% versus approximately 2.4% on placebo. Among participants who adhered fully to treatment throughout the trial, that figure rose to around 17%. Both numbers come with the usual caveat that clinical trial populations and real-world results can differ. People already established on the 2.4mg weekly injection may be able to move to the 25mg tablet, but that is a clinical decision made with a prescriber. Wegovy tablets are not currently available on the NHS; a NICE appraisal would be needed first. You can read more on our page covering the new semaglutide formulations.

One practical check worth doing before any online search: look up any pharmacy offering semaglutide on the GPhC register before handing over any personal information. It takes under a minute and tells you immediately whether you are dealing with a registered UK pharmacy.

What did the MHRA's January 2026 safety update say, and should it change anyone's thinking?

Safety news travels unevenly, and the January 2026 MHRA Drug Safety Update for GLP-1 medicines is worth knowing about directly rather than through secondhand summaries. The update highlighted acute pancreatitis as a known but infrequent side effect that can be serious. The specific signal to act on: severe stomach pain that comes on persistently and radiates to the back, with or without vomiting. That warrants urgent medical attention, not a wait-and-see approach.

The broader GI side-effect picture (nausea, loose stools, constipation, indigestion, fatigue) remains the most common experience for people starting semaglutide. These effects tend to be most noticeable after starting treatment or after a dose increase, and they generally settle within a couple of weeks. The MHRA update did not revise the overall benefit-risk assessment for these medicines; it added a clear, specific instruction for a particular symptom pattern. If you want to report a suspected side effect, the Yellow Card scheme accepts reports directly from patients and carers, not just healthcare professionals.

Anyone with a personal or family history of pancreatitis, or with other relevant conditions, should discuss that with a prescriber before starting. Our page on Wegovy and mood covers the mental health side-effect questions that come up regularly alongside the GI ones.

What is semaglutide's new MASH indication, and does it affect weight-loss treatment?

On 3 July 2026 the MHRA granted conditional approval for semaglutide (Wegovy) to treat MASH (metabolic dysfunction-associated steatohepatitis, a form of fatty liver disease) in adults with moderate-to-advanced fibrosis. This is a third licensed indication for the same medicine, alongside weight management and the reduction of major cardiovascular event risk in eligible adults.

For people using semaglutide for weight loss, this development does not change their treatment. The licence for weight management remains as it was: adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. A prescriber assesses the whole picture. The MASH approval does, though, reinforce something clinically important: the effects of sustained weight reduction reach beyond the number on the scale, and regulators are now acknowledging that in formal licensing terms. If you are following the latest Wegovy approvals and updates, the MASH indication is one of the more significant regulatory moments of the year.

For a full comparison of what semaglutide and tirzepatide each offer, our weight-loss treatment overview sets out both options side by side in plain language, without the press-release framing. If you are thinking about whether treatment might suit your situation, speaking to our prescribers is the right starting point, a real clinician reads your consultation the same day, and there is no cost for the assessment itself.